CongressTrades

JAZZ

PHARMACEUTICAL PREPARATIONS

Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ) [ST]

www.jazzpharmaceuticals.com ↗
$226.12

▲ 0.00%

prev close

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Congressional Trades

2

All tracked trades

Members Trading

1

Unique members

Net Activity

+0

1 buys · 1 sells

Members Who Traded This Stock

2 trade events

2023-07-12

Daniel Goldman

JAZZ

Sell

Amount

$15,001 - $50,000

Filed

1025d ago

2023-03-06

Daniel Goldman

JAZZ

Buy

Amount

$15,001 - $50,000

Filed

1143d ago

Recent News

Powered by Polygon.io

Zymeworks Announces Participation in Upcoming Investor Conferences

GlobeNewswire Inc.·2026-05-13

Pheochromocytoma and Paraganglioma Market to Exhibit Growth at 7.3% CAGR by 2036 Driven by the Advent of Drug Classes Such as SSTR2 analogs, Dopamine Receptor D2 Agonists, TAAs or TSAs, and Others | DelveInsight

GlobeNewswire Inc.·2026-04-20

Artios Strengthens Leadership Team to Accelerate Late-Stage Development of Potential First-in-Class Oncology Pipeline

GlobeNewswire Inc.·2026-02-16

Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026

GlobeNewswire Inc.·2026-02-12

Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed?

The Motley Fool·2026-01-27

Trade Timeline

Congressional activity, newest first

Daniel Goldman

2023-07-12 · Sale

$15,001 - $50,000

Daniel Goldman

2023-03-06 · Purchase

$15,001 - $50,000